Back to search
FDAFDA · Food and drugs·Recall number D-0144-2019

Bi-Mix (Papaverine/Phentolamine 150 mg/5 mg) a) Injectable NDC 69699-1760-15; b) (LYO) Powder NDC 69699-1760-15, Pharm D Solutions, Houston, Texas

Published November 7, 2018 · Recall initiated: September 10, 2018

Summary

FDA records drug Class II recall D-0144-2019, published November 7, 2018 and initiated September 10, 2018. Recalling firm: Pharm D Solutions, LLC; Status: Terminated; Reported quantity: 29 vials; Lot: Lots: a)04032018:49 Discard by: 9/30/2018; 05242018:72 Discard by: 11/20/2018; b) 06192018:08 Discard by: 12/16/2018; 06132018:29 Discard by: 12/10/2018. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility

What to do

Voluntary: Firm initiated · Press Release

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Pharm D Solutions, LLC
Distributor
Nationwide
Lot
Lots: a)04032018:49 Discard by: 9/30/2018; 05242018:72 Discard by: 11/20/2018; b) 06192018:08 Discard by: 12/16/2018; 06132018:29 Discard by: 12/10/2018
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Bi-Mix (Papaverine/Phentolamine 150 mg/5 mg) a) Injectable NDC 69699-1760-15; b) (LYO) Powder NDC 69699-1760-15, Pharm D Solutions, Houston, Texas recalled?

Yes. FDA published recall D-0144-2019 on November 7, 2018. Reported hazard: Lack of Assurance of Sterility

What should I do if I have this product?

Voluntary: Firm initiated · Press Release